ORIC Pharmaceuticals, Inc. (ORIC)
- Previous Close
9.60 - Open
9.61 - Bid 9.49 x 200
- Ask 9.55 x 200
- Day's Range
9.48 - 9.86 - 52 Week Range
4.91 - 16.65 - Volume
359,803 - Avg. Volume
580,285 - Market Cap (intraday)
640.512M - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
-- - EPS (TTM)
-1.80 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
www.oricpharma.comRecent News: ORIC
Performance Overview: ORIC
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORIC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORIC
Valuation Measures
Market Cap
641.19M
Enterprise Value
327.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.70%
Return on Equity (ttm)
-38.30%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-101.76M
Diluted EPS (ttm)
-1.80
Balance Sheet and Cash Flow
Total Cash (mrq)
316.78M
Total Debt/Equity (mrq)
2.95%
Levered Free Cash Flow (ttm)
-57.98M
Research Analysis: ORIC
Company Insights: ORIC
ORIC does not have Company Insights